EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses

EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses

Over the last decade, therapies targeting immune checkpoints, such as programmed death-1 (PD-1), have revolutionized the field of cancer immunotherapy. However, low response rates and immune-related adverse events remain a major concern. Here, we report that epigallocatechin gallate (EGCG), the most...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Dinoop Ravindran Menon, Yang Li, Takeshi Yamauchi, Douglas Grant Osborne, Prasanna Kumar Vaddi, Michael F Wempe, Zili Zhai, Mayumi Fujita
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
EGCG
PD-L1
PD-L2
melanoma immunotherapy
IFN-γ signaling
JAK-STAT signaling
Medicine
R
Pharmacy and materia medica
RS1-441
Acceso en línea:https://doaj.org/article/6cf323d74bc0482fa07dc2a10f04c798
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/6cf323d74bc0482fa07dc2a10f04c798

Ejemplares similares